J. Stasko et al., SOME HEMOSTATIC CHANGES DURING THE COURSE OF HEMODIALYSIS IN PATIENTSWITH ERYTHROPOIETIN TREATMENT, Clinical and applied thrombosis/hemostasis, 3(2), 1997, pp. 141-143
The recombinant human erythropoietin (rHuEPO), an effective agent in t
he treatment of renal anemia, can predispose chronic uremic patients t
o thrombotic events with regular hemodialysis (HD). It has been propos
ed that increased release of tissue plasminogen activator (t-PA) from
endothelial cells, together with consumption of plasminogen activator
inhibitor-1 (PAI-1), is likely to be a leading cause of enhanced fibri
nolytic activity (FA) during HD. In our study, rHuEPO-treated patients
manifested PAI-1 Ag (antigen) plasma levels that were significantly a
ugmented after HD, suggesting FA inhibition during the HD session. The
elevated predialysis beta-thromboglobulin (BTG) and platelet factor-4
(PF-4) plasma levels were increased in rHuEPO-treated patients during
HD; the platelet protein levers were simultaneously decreased in the
control group. Both findings reflect decreased FA and greater activity
of platelets in the course of HD with administration of rHuEPO and a
possible correlation of these mechanisms with the questioned prothromb
otic performance of rHuEPO.